Avatar

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maintenance Approaches

By Nina Shah 4 Videos
August 29, 2017
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Scripps MD Anderson Cancer Center

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology 2021

Sat, Feb 20, 2021
The Royal Marsden School

Demystifying the Science Behind Targeted Treatments for Haematological C...

Tue, Feb 2, 2021
Total Health Conferencing

Virtual West Oncology Conference

Fri, Feb 26, 2021
16:22
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Newly Diagnosed MM: Can VMP Combination Improve PFS...

Feat. P. Voorhees
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, I...

Feat. K. Shain
14:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on HDT in Frontline MM: Is Lenalidomide, Bortezomib...

Feat. A. Nooka
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and...

14:16
2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do T...

Feat. K. Anderson
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therap...

Feat. A. Rosko
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs, mSMART Classi...

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

08:40
Surbhi Sidana

Duration of Complete Response Impacts Overall Survival in Multiple Myeloma

16:06
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Smoldering MM: Why Should We Not Treat It Early?

Feat. A. Dispenzieri
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018